Relevance of Interleukins 6 and 8 Single Nucleotide Polymorphisms in Prostate Cancer: A Multicenter Study
Table 3
Comparison of genotype ratios of IL-6 rs1800795 and IL-8 rs2227306 SNPs in the affected and the control groups.
Frequencies of genotypes
Cancer versus control®
BPH versus control®
Cancer (n = 40)
BPH (n = 40)
Control (n = 40)
1
OR1 (95%CI) (LL–UL)
2
OR2 (95%CI) (LL–UL)
IL-6 rs1800795
CC versus (CG + GG)
8 (20%)
9 (22.5%)
25 (62.5%)
<0.001
0.1500 (0.055–0.410)
<0.001
0.174 (0.065–0.464)
CG versus (CC + GG)
14 (35%)
25 (62.5%)
12 (30%)
0.633
1.256 (0.492–3.209)
0.004
3.889 (1.533–9.868)
GG versus (CC + CG)
18 (45%)
6 (15%)
3 (7.5%)
0.001
10.091 (2.665–38.204)
0.297
2.177 (0.504–9.391)
IL-8 rs2227306
CC versus (CT + TT)
12 (30%)
3 (7.5%)
2 (5%)
0.009
8.143 (1.686–39.319)
0.646
1.541 (0.243–9.755)
CT versus (CC + TT)
17 (42.5%)
24 (60%)
16 (40%)
0.820
1.109 (0.455–2.701)
0.076
2.250 (0.920–5.504)
TT versus (CC + CT)
11 (27.5%)
13 (32.5%)
22 (55%)
0.014
0.310 (0.122–0.789)
0.045
0.394 (0.159–0.978)
®: reference group, OR: odds ratio, CI: confidence interval, UL: upper limit, LL: lower limit. OR1, 1: odds ratio and value for comparing between cancer and control. OR2, 2: odds ratio and p value for comparing between BPH and control. Statistically significant at ≤ 0.05.